CompletedPhase 2NCT05179668

SGLT2 Inhibition in Hemodialysis

Studying Complication in hemodialysis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Medical University of Vienna
Principal Investigator
Manfred Hecking, MD, PhD
Medical University of Vienna, Department of Medicine III, Division of Nephrology and Dialysis
Intervention
Dapagliflozin 10 MG(drug)
Enrollment
220 target
Eligibility
18 years · All sexes
Timeline
20222026

Study locations (9)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05179668 on ClinicalTrials.gov

Other trials for Complication in hemodialysis

Additional recruiting or active studies for the same condition.

See all trials for Complication in hemodialysis

← Back to all trials